Pharma giant facing into expiry of key patents and investors are becoming itchy
Fear of overpaying cools mergers and acquisitions activity to $753 billion in quarter
Company’s shares down 1.3% in premarket trading after it says it will not separate
Irish shares fare better than wider European market, with Kingspan’s 7% rise leading way
Sanofi, Merck, Celgene and Gilead Sciences also believed to have been interested in firm
French pharma firm courts cancer group Medivation as key drugs face generics
French drugmaker’s advances have been rebuffed
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices